Skip to main navigation Skip to search Skip to main content

A comprehensive care pathway of gene therapy for hemophilia based on current guideline documents and summary of product characteristics: communication from the ISTH SSC working group on gene therapy

  • Caroline M. A. Mussert
  • , Wolfgang Miesbach
  • , Pratima Chowdary
  • , David Lillicrap
  • , Johnny Mahlangu
  • , Flora Peyvandi
  • , Steven W. Pipe
  • , Alok Srivastava
  • , Jan Voorberg
  • , Glenn F. Pierce
  • , Radoslaw Kaczmarek
  • , Paul Batty
  • , Ilaria Cutica
  • , Amit Nathwani
  • , Frank W. G. Leebeek*
  • *Corresponding author for this work
  • Erasmus University Rotterdam
  • Goethe University Frankfurt
  • Royal Free London NHS Foundation Trust
  • University College London
  • Queen's University Kingston
  • University of the Witwatersrand
  • University of Milan
  • IRCCS Fondazione Ca'Granda – Ospedale Maggiore Policlinico - Milano
  • University of Michigan, Ann Arbor
  • St. John's National Academy of Health Sciences
  • Sanquin Blood Supply Foundation
  • World Federation of Hemophilia
  • Indiana University Bloomington
  • Ludwik Hirszfeld Institute of Immunology and Experimental Therapy of the Polish Academy of Sciences

Research output: Contribution to journalArticleAcademicpeer-review

29 Downloads (Pure)

Abstract

Background Gene therapy for hemophilia has recently been implemented as standard clinical care, requiring organizational and multistakeholder preparedness and clear guidelines. In addition to pharmaceutical summaries of product characteristics (SMPCs), various (inter)national guidance documents have been published. However, no guidance document or SMPC covers the entire gene therapy care pathway. Objectives This study provides a complete and comprehensive overview of current guidance documents and SMPCs to develop a comprehensive care pathway for hemophilia gene therapy delivery. Methods Published gene therapy guidance documents and collected SMPCs were complemented by a selective search in online databases, including PubMed and scientific societies’ websites. Reference lists were checked for additional relevant articles. Results Four SMPCs and 11 (inter)national guidance documents and recommendations were collected. The documents were focused on either the intervention or the care pathway, and none were comprehensive covering all aspects of hemophilia gene therapy delivery. Considerable differences were found between the 2 approved gene therapy products and between the SMPCs issued by the 2 regulatory authorities, the Food and Drug Administration and the European Medicines Agency. (Inter)national guidance documents provided additional information and recommendations not covered in SMPCs. Conclusion Based on SMPCs and (inter)national guidance documents and recommendations a care pathway has been developed and visualized in a Metro Map. This provides a clear and comprehensive overview of all activities, contact moments, and responsibilities within the longitudinal gene therapy treatment process. This comprehensive care pathway may help navigate gene therapy implementation, providing guidance to clinicians, patients, and caregivers.
Original languageEnglish
JournalJournal of thrombosis and haemostasis
DOIs
Publication statusE-pub ahead of print - 2025

Fingerprint

Dive into the research topics of 'A comprehensive care pathway of gene therapy for hemophilia based on current guideline documents and summary of product characteristics: communication from the ISTH SSC working group on gene therapy'. Together they form a unique fingerprint.

Cite this